Evaluation of the effect of curcumin-piperine supplement administration on the severity of injury and function in patients with acute ischemic stroke

Investigating the effect of curcumin-piperine supplementation on the severity of acute ischemic stroke based on the NIHSS criteria

This study is a double-blind clinical trial that will be conducted on 68 patients with acute ischemic stroke admitted to the neurology department and who meet the conditions for entering the study.

Neurological emergency and neurology department of Ghaem Hospital

Criteria for entering the study: 1- Age between 50 and 80 years 2- Less than 24 hours have passed since the start of the stroke. 3- The patient has been diagnosed with an acute ischemic stroke. 4- The GCS of the patient should be more than 13 at the time of the visit. 5- The range of NIHSS is between 5 and 20. 6- MRS should be less than 2 before the onset of stroke. 7- Signing the informed consent form Criteria for not entering the study: 1- Patients receiving rtPA 2- Candidate patients for endovascular treatment, mechanical thrombectomy, or craniotomy 3- Pregnancy or breastfeeding 4- History of allergy to turmeric or black pepper 5- Taking immunosuppressive drugs 6- Simultaneously receiving any drug or supplement with an antioxidant or anti-inflammatory effect or an approved immune system regulator Exclusion criteria: 1- Occurrence of severe side effects during the study 2- The patient's unwillingness to continue the study

34 patients in the curcumin-piperine supplement group, as soon as possible after confirming the diagnosis of acute ischemic stroke, will receive curcumin-piperine tablets at a dose of 500/5 mg twice a day for 4 days along with standard treatment.

Injury severity after acute ischemic stroke based on NIHSS Patient performance after acute ischemic stroke based on MRS and BI

Replacement blocks using the site https://www.sealedenvelope.com with the explanation that each of the blocks has 4 members and the shape of the blocks can be as follows, for example: [ABAB], [BBAA], [BABA], … Codes A and B are randomly assigned to intervention and control groups. The site mentioned above randomly selects 17 blocks out of all four possible blocks to include all patients in the study.

In this study, only the DUE unit expert has full knowledge of the type of drug received (placebo or curcumin-piperine supplement) and this person has no role in prescribing, evaluating treatment, and analyzing data. Patients who meet the conditions for entering the study are randomly assigned to one of the groups by the aforementioned expert based on the set codes. Then the pills are placed in the hands of researchers who are unaware of the content of the codes and the type of pills, and they are prescribed. The placebo tablet looks completely similar to the curcumin-piperine tablet and contains the same ingredients except for the active ingredient. Therefore, it is not possible to distinguish pills from each other by patients and clinical caregivers.